Meeting NewsVideo

VIDEO: Top clinical challenges in major depression

NEW ORLEANS — In this video, Michael E. Thase, MD, of Perelman School of Medicine, University of Pennsylvania, discusses significant clinical challenges in major depression, as reported by past Psych Congress attendees.

Challenges include screening and assessment, using antidepressants, and treatment-resistant depression.

“We should stay engaged and keep our patients engaged in treatment, address their condition as decisively as we can, keep track of how we’re doing, move forward through our treatment algorithms when our initial or even second line treatments aren’t working,” he said.

Disclosures: Thase reports serving on the advisory board for Acadia, Alkermes, Allergan (Forest, Naurex), AstraZeneca, Cerecor, Eli Lilly, Fabre-Kramer Pharmaceuticals, Inc., Gerson Lehrman Group, Guidepoint Global, Johnson & Johnson (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Inc., Merck, Moksha8, Nestlé (PamLab), Novartis, Otsuka, Pfizer, Shire, Sunovion, Takeda; consulting for Acadia, Alkermes, Allergan (Forest, Naurex), AstraZeneca, Cerecor, Eli Lilly, Fabre-Kramer Pharmaceuticals, Inc., Gerson Lehrman Group, Guidepoint Global, Johnson & Johnson (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Inc., Merck, Moksha8, Nestlé (PamLab), Novartis, Otsuka, Pfizer, Shire, Sunovion, Takeda; spouse employment with Peloton Advantage (does business with AstraZeneca and Pfizer); holding equity in MedAvante, Inc.; receiving grant support from Agency for Healthcare Research and Quality, Alkermes, AssureRx, Avanir, Forest Pharmaceuticals, Janssen, Intracellular, National Institute of Mental Health, Otsuka Pharmaceuticals, Takeda; and receiving royalties from the American Psychiatric Foundation, Guilford Publications, Herald House, W.W. Norton & Company, Inc.

NEW ORLEANS — In this video, Michael E. Thase, MD, of Perelman School of Medicine, University of Pennsylvania, discusses significant clinical challenges in major depression, as reported by past Psych Congress attendees.

Challenges include screening and assessment, using antidepressants, and treatment-resistant depression.

“We should stay engaged and keep our patients engaged in treatment, address their condition as decisively as we can, keep track of how we’re doing, move forward through our treatment algorithms when our initial or even second line treatments aren’t working,” he said.

Disclosures: Thase reports serving on the advisory board for Acadia, Alkermes, Allergan (Forest, Naurex), AstraZeneca, Cerecor, Eli Lilly, Fabre-Kramer Pharmaceuticals, Inc., Gerson Lehrman Group, Guidepoint Global, Johnson & Johnson (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Inc., Merck, Moksha8, Nestlé (PamLab), Novartis, Otsuka, Pfizer, Shire, Sunovion, Takeda; consulting for Acadia, Alkermes, Allergan (Forest, Naurex), AstraZeneca, Cerecor, Eli Lilly, Fabre-Kramer Pharmaceuticals, Inc., Gerson Lehrman Group, Guidepoint Global, Johnson & Johnson (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Inc., Merck, Moksha8, Nestlé (PamLab), Novartis, Otsuka, Pfizer, Shire, Sunovion, Takeda; spouse employment with Peloton Advantage (does business with AstraZeneca and Pfizer); holding equity in MedAvante, Inc.; receiving grant support from Agency for Healthcare Research and Quality, Alkermes, AssureRx, Avanir, Forest Pharmaceuticals, Janssen, Intracellular, National Institute of Mental Health, Otsuka Pharmaceuticals, Takeda; and receiving royalties from the American Psychiatric Foundation, Guilford Publications, Herald House, W.W. Norton & Company, Inc.

    See more from U.S. Psychiatric & Mental Health Congress